

---

## WilmerHale Counsels Syros Pharmaceuticals in \$35M Private Placement

APRIL 26, 2017

Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced that it has entered into a stock purchase agreement with several institutional accredited investors for the private placement of 2,592,591 shares of common stock at a purchase price of \$13.50 per share, yielding expected gross proceeds of \$35 million.

The WilmerHale team counseling Syros included [Steven Singer](#), [Cynthia Mazareas](#), [Mhairi Immermann](#), and Killian Nolan.

Read Syros Pharmaceuticals' [press release](#) for more information.